Integrin αvβ3-targeted radiotracer 99mTc-3P-RGD2 useful for noninvasive monitoring of breast tumor response to antiangiogenic linifanib therapy but not anti-integrin αvβ3 RGD2 therapy

Theranostics

Volumn 3, Issue 11, 2013, Pages 816-830

  Ji, Shundong ^a   Zheng, Yumin ^a,b   Shao, Guoqiang ^a   Zhou, Yang ^a   Liu, Shuang ^a  

^a PURDUE UNIVERSITY   (United States)

^b CHINA JAPAN FRIENDSHIP HOSPITAL   (China)

Author keywords

99mTc 3P RGD2.; Integrin v 3; Linifanib; Monitoring antiangiogenic therapy

Indexed keywords

ARGINYLGLYCYLASPARTIC ACID DIMER [54,55] TC 99M; CD31 ANTIGEN; EOSIN; HEMATOXYLIN; LINIFANIB; TRACER; UNCLASSIFIED DRUG; VITRONECTIN RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC THERAPY; ARTICLE; BREAST TUMOR; COMPUTER ASSISTED TOMOGRAPHY; DRUG RESPONSE; EPIDIDYMIS FAT; FEMALE; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; LONGITUDINAL STUDY; MOUSE; NONHUMAN; NUDE MOUSE; PROTEIN EXPRESSION; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TUMOR VASCULARIZATION; TUMOR VOLUME; TUMOR XENOGRAFT;

AND 99MTC-3P-RGD2.; INTEGRIN ΑVΒ3; LINIFANIB; MONITORING ANTIANGIOGENIC THERAPY;

ANIMALS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; DISEASE MODELS, ANIMAL; DRUG MONITORING; INDAZOLES; INTEGRIN ALPHAVBETA3; MICE; PHENYLUREA COMPOUNDS; RADIOACTIVE TRACERS; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TREATMENT OUTCOME;

EID: 84888793527     PISSN: None     EISSN: 18387640     Source Type: Journal    
DOI: 10.7150/thno.6989     Document Type: Article

References (69)

1. Folkman J. Role of angiogenesis in tumor growth and metastasis. Semin Oncol 2002;29:15-18.
2. Mousa SA. Anti-integrin as novel drug-discovery targets: potential therapeutic and diagnostic implications. Curr Opin Chem Biol 2002;6:534-541.
3. Guo W, Giancotti FG. Integrin signalling during tumour progression. Nat Rev Mol Cell Biol 2004;5:816-826.
4. Felding-Habermann B. Integrin adhesion receptors in tumor metastasis. Clin Exp Metastasis 2003;20:203-213.
5. Bergers G, Benjamin LE. Tumorigenesis and the angiogenic switch. Nat Rev Cancer 2003;3:401-410.
6. Bergers G, Song S, Meyer-Morse N, Bergsland E, Hanahan D. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest 2003;111:1287-1295.
7. Ferrara N, Kerbel RS. Angiogenesis as a therapeutic target. Nature 2005;438:967-974.
8. Haddley K. Linifanib Receptor tyrosine kinase inhibitor Oncolytic. Drug Future 2010;35:106-112.
9. Zhou J, Goh BC, Albert DH, Chen CS. ABT-869, a promising multi-targeted tyrosine kinase inhibitor: from bench to bedside. J Hematol Oncol 2009;2:33-45.
10. Jiang F, Albert DH, Luo Y, Tapang P, Zhang K, Davidsen SK, Fox GB, Lesniewski R, McKeegan EM. ABT-869, a multitargeted receptor tyrosine kinase inhibitor, reduces tumor microvascularity and improves vascular wall integrity in preclinical tumor models. J Pharmacol Exp Ther 2011;338:134-142.
11. Shankar DB, Li J, Tapang P, Owen McCall J, Pease LJ, Dai Y, Wei RQ, Albert DH, Bouska JJ, Osterling DJ, Guo J, Marcotte PA, Johnson EF, Soni N, Hartandi K, Michaelides MR, Davidsen SK, Priceman SJ, Chang JC, Rhodes K, Shah N, Moore TB, Sakamoto KM, Glaser KB. ABT-869, a multitargeted receptor tyrosine kinase inhibitor: inhibition of FLT3 phosphorylation and signaling in acute myeloid leukemia. Blood 2007;109:3400-3408.
12. Hernandez-Davies JE, Zape JP, Landaw EM, Tan X, Presnell A, Griffith D, Heinrich MC, Glaser KB, Sakamoto KM. The multitargeted receptor tyrosine kinase inhibitor linifanib (ABT-869) induces apoptosis through an Akt and glycogen synthase kinase 3β-dependent pathway. Mol Cancer Ther 2011;10:949-959.
13. Zhang Y, Cole T, Tapang P, Luo F, Hradil V, Jiang F, Luo Y, Albert D, Fox GB. Total lesion glycolysis and FDG SUV as early readouts of tumor response to Linifanib (ABT-869) in SCID mice with HT1080 xenografts. J Nucl Med 2010;51:111.
14. Luo Y, Jiang F, Cole TB, Hradil VP, Reuter D, Chakravartty A, Albert DH, Davidsen SK, Cox BF, McKeegan EM, Fox GB. A novel multi-targeted tyrosine kinase inhibitor, linifanib (ABT-869), produces functional and structural changes in tumor vasculature in an orthotopic rat glioma model. Cancer Chemother Pharmacol 2012;69:911-921.
15. Wong CI, Koh TS, Soo R, Hartono S, Thng CH, McKeegan E, Yong WP, Chen CS, Lee SC, Wong J, Lim R, Sukri N, Lim SE, Ong AB, Steinberg J, Gupta N, Pradhan R, Humerickhouse R, Goh BC. Phase I and biomarker study of ABT-869, a multiple receptor tyrosine kinase inhibitor, in patients with refractory solid malignancies. J Clin Oncol 2009;27:4718-4726.
16. Tannir NM, Wong YN, Kollmannsberger CK, Ernstoff MS, Perry DJ, Appleman LJ, Posadas EM, Cho D, Choueiri TK, Coates A, Gupta N, Pradhan R, Qian J, Chen J, Scappaticci FA, Ricker JL, Carlson DM, Michaelson MD. Phase 2 trial of linifanib (ABT-869) in patients with advanced renal cell cancer after sunitinib failure. Eur J Cancer. 2011;47:2706-2714.
17. Foote RL, Weidner N, Harris J, Hammond E, Lewis JE, Vuong T, Ang KK, Fu KK. Evaluation of tumor angiogenesis measured with microvessel density (MVD) as a prognostic indicator in nasopharyngeal carcinoma: results of RTOG 9505. Int J Radiat Oncol Biol Phys 2005;61:745-753.
18. El-Assal ON, Yamanoi A, Soda Y, Yamaguchi M, Igarashi M, Yamamoto A, Nabika T, Nagasue N. Clinical significance of microvessel density and vascular endothelial growth factor expression in hepatocellular carcinoma and surrounding liver: possible involvement of vascular endothelial growth factor in the angiogenesis of cirrhotic liver. Hepatology 1998;27:1554-1562.
19. O'Connor JP, Jackson A, Parker GJ, Jayson GC. DCE-MRI biomarkers in the clinical evaluation of antiangiogenic and vascular disrupting agents. Br J Cancer 2007;96:189-195.
20. Checkley D, Tessier JJ, Kendrew J, Waterton JC, Wedge SR. Use of dynamic contrast-enhanced MRI to evaluate acute treatment with ZD6474, a VEGF signalling inhibitor, in PC-3 prostate tumours. Br J Cancer 2003;89:1889-1895.
21. Evelhoch JL, LoRusso PM, He Z, DelProposto Z, Polin L, Corbett TH, Langmuir P, Wheeler C, Stone A, Leadbetter J, Ryan AJ, Blakey DC, Waterton JC. Magnetic resonance imaging measurements of the response of murine and human tumors to the vascular-targeting agent ZD6126. Clin Cancer Res 2004;10:3650-3657.
22. Bauerle T, Komljenovic D, Merz M, Berger MR, Goodman SL, Semmler W. Cilengitide inhibits progression of experimental breast cancer bone metastases as imaged noninvasively using VCT, MRI and DCE-MRI in a longitudinal in vivo study. Int J Cancer 2011;128:2453-2462.
23. 3 expression by bone-residing breast cancer metastases. Diagn Mol Pathol 1996;5:127-135.
24. 3 integrin receptors in breast tumor. J Exp Clin Cancer Res 2001;20:585-590.
25. 3: a new prognostic indicator in breast cancer. Clin Cancer Res 1998;4:2625-2634.
26. 3 in prostate cancer progression. Neoplasia 2002;4:191-194.
27. Carreiras F, Denoux Y, Staedel C, Lehmann M, Sichel F, Gauduchon P. Expression and localization of αv integrins and their ligand vitronectin in normal ovarian epithelium and in ovarian carcinoma. Gynecol Oncol 1996;62:260-267.
28. Falcioni R, Cimino L, Gentileschi MP, D'Agnano I, Zupi G, Kennel SJ, Sacchi A. Expression of β1, β3, β4, and β5 integrins by human lung carcinoma cells of different histotypes. Exp Cell Res 1994;210:113-122.
29. 3 integrin and intercellular adhesion molecule-1 expression in cutaneous malignant melanoma lesions. Cancer Res 1997;57:1554-1560.
30. Gingras MC, Roussel E, Bruner JM, Branch CD, Moser RP. Comparison of cell adhesion molecule expression between glioblastoma multiforme and autologous normal brain tissue. J Neuroimmunol 1995;57:143-153.
31. 3 and αvβ5 integrin expression in glioma periphery. Neurosurgery 2001;49:380-389.
32. Felding-Habermann B, O'Toole TE, Smith JW, Fransvea E, Ruggeri ZM, Ginsberg MH, Hughes PE, Pampori N, Shattil SJ, Saven A, Mueller BM. Integrin activation controls metastasis in human breast cancer. Proc Natl Acad Sci U S A 2001;98:1853-1858.
33. Shattil SJ. Signaling through platelet integrin αIIbβ3: inside-out, outside-in, and sideways. Thromb Haemost 1999;82:318-325.
34. 3 expression confers on tumor cells a greater propensity to metastasize to bone. FASEB J 2002;16:1266-1268.
35. 3 integrin expression with the metastatic potential and migratory and chemotactic ability of human osteosarcoma cells. Clin Exp Metastasis 2004;21:747-753.
36. Zitzmann S, Ehemann V, Schwab M. Arginine-glycine-aspartic acid (RGD)-peptide binds to both tumor and tumor-endothelial cells in vivo. Cancer Res 2002;62:5139-5143.
37. Meyer A, Auernheimer J, Modlinger A, Kessler H. Targeting RGD recognizing integrins: drug development, biomaterial research, tumor imaging and targeting. Curr Pharm Des 2006;12:2723-2747.
38. 3-targeted radiotracers: maximizing binding affinity via bivalency. Bioconjug Chem 2009;20:2199-2213.
39. Zhou Y, Chakraborty S, Liu S. Radiolabeled Cyclic RGD Peptides as Radiotracers for Imaging Tumors and Thrombosis by SPECT. Theranostics 2011;1:58-82.
40. Mahabeleshwar GH, Feng W, Reddy K, Plow EF, Byzova TV. Mechanisms of integrin-vascular endothelial growth factor receptor cross-activation in angiogenesis. Circ Res 2007;101:570-580.
41. 3 integrin in the activation of vascular endothelial growth factor receptor-2. EMBO J 1999;18:882-892.
42. Somanath PR, Ciocea A, Byzova TV. Integrin and growth factor receptor alliance in angiogenesis. Cell Biochem Biophys 2009;53:53-64.
43. 3-integrin expression with 18F-fluciclatide for assessment of response to targeted therapy: ready for prime time? J Nucl Med 2011;52:335-337.
44. Morrison MS, Ricketts SA, Barnett J, Cuthbertson A, Tessier J, Wedge SR. Use of a novel Arg-Gly-Asp radioligand, 18F-AH111585, to determine changes in tumor vascularity after antitumor therapy. J Nucl Med 2009;50:116-122.
45. 3-integrin and αvβ5-integrin imaging agent. J Nucl Med 2011;52:424-430.
46. 3 function as a predictor of the antimigratory and antiproliferative effects of dasatinib. Cancer Res 2009;69:3173-3179.
47. Meyer A, Auernheimer J, Modlinger A, Kessler H. Targeting RGD recognizing integrins: drug development, biomaterial research, tumor imaging and targeting. Curr Pharm Des 2006;12:2723-2747.
48. Cai W, Chen X. Multimodality molecular imaging of tumor angiogenesis. J Nucl Med 2008;49 (Suppl 2):113-128.
49. Dijkgraaf I, Boerman OC. Molecular imaging of angiogenesis with SPECT. Eur J Nucl Med Mol Imaging 2010;37 (Suppl 1):104-113.
50. Niu G, Chen X. Has molecular and cellular imaging enhanced drug discovery and drug development? Drugs R D 2008;9:351-368.
51. 3-targeted PET Tracers. Curr Med Chem 2012;19:3301-3309.
52. Haubner R, Wester HJ. Radiolabeled tracers for imaging of tumor angiogenesis and evaluation of anti-angiogenic therapies. Curr Pharm Des 2004;10:1439-1455.
53. Michalski MH, Chen X. Molecular imaging in cancer treatment. Eur J Nucl Med Mol Imaging 2011; 38: 358-377.
54. 99mTc-labeled cyclic RGD dimers with PEG4 linkers. Mol Pharm 2009; 6:231-245.
55. 2 in non-human primates. Mol Imaging Biol 2011;13:730-736.
56. 3 expression. Mol Imaging 2011;10:386-397.
57. 3. Mol Imaging 2013;12:39-48.
58. 2. Theranostics 2012;2:577-588.
59. Suzuki M, Mose ES, Montel V, Tarin D. Dormant cancer cells retrieved from metastasis-free organs regain tumorigenic and metastatic potency. Am J Pathol 2006;169:673-681.
60. Sellappan S, Grijalva R, Zhou X, Yang W, Eli MB, Mills GB, Yu D. Lineage infidelity of MDA-MB-435 cells: expression of melanocyte proteins in a breast cancer cell line. Cancer Res 2004;64:3479-3485.
61. Ellison G, Klinowska T, Westwood RF, Docter E, French T, Fox JC. Further evidence to support the melanocytic origin of MDA-MB-435. Mol Pathol 2002;55:294-299.
62. Chambers AF. MDA-MB-435 and M14 cell lines: identical but not M14 melanoma? Cancer Res 2009; 69:5292-5293.
63. Jain RK. Transport of molecules in the tumor interstitium: a review. Cancer Res 1987;47:3039-3051.
64. 2. J Pharmacol Exp Ther 2013;346:251-258.
65. Shi J, Zhou Y, Chakraborty S, Kim YS, Jia B, Wang F, Liu S. Evaluation of 111In-labeled cyclic RGD peptides: effects of peptide and PEG4 multiplicity on their tumor uptake, excretion kinetics and metabolic stability. Theranostics 2011;1:322-340.
66. 99mTc chelates on biological properties. Bioconjug Chem 2012;23:586-595.
67. 3 expression using 64Cu-labeled tetrameric RGD peptide. J Nucl Med 2005; 46: 1707-1718.
68. 3 expression using 18F-labeled PEGylated tetrameric RGD peptide (18F-FPRGD4). J Nucl Med 2007;48: 1536-1544.
69. Reynolds AR, Hart IR, Watson AR, Welti JC, Silva RG, Robinson SD, Violante GD, Gourlaouen M, Salih M, Jones MC, Jones DT, Saunders G, Kostourou V, Perron-Sierra F, Norman JC, Tucker GC, Hodivala-Dilke KM. Stimulation of tumor growth and angiogenesis by low concentrations of RGD-mimetic integrin inhibitors. Nat Med 2009;15: 392-400.